Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.49 |
| ▸ | PDE8B | O95263 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | GRK6 | P43250 | 2/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14225457 | 0.89 | TLR7 (0.50) | ADORA2AADORA1ADORA2BADORA3TLR7 | |
| SCHEMBL1146422 | 0.79 | TLR7 (0.53) | ADORA2AADORA1ADORA2BADORA3TLR7 | |
| SCHEMBL10121588 | 0.78 | ADORA2A (0.38) | ADORA2AADORA1ADORA2BADORA3TLR7 | |
| SCHEMBL1847650 | 0.74 | HSP90AA1 (0.42) | ADORA2AADORA1ADORA2BHSP90AA1HSP90AB1 | |
| SCHEMBL10174179 | 0.74 | ADORA2A (0.48) | ADORA2AADORA1ADORA2BADORA3TLR7 | |
| SCHEMBL13233221 | 0.72 | ADORA2A (0.49) | ADORA2AADORA1ADORA2BADORA3TLR7 | |
| SCHEMBL13233223 | 0.71 | ADORA2A (0.56) | ADORA2AADORA1ADORA2BADORA3PDE8B | |
| SCHEMBL1001748 | 0.69 | TLR7 (0.64) | ADORA2AADORA1ADORA2BADORA3TLR7 | |
| SCHEMBL25515677 | 0.69 | TLR7 (0.56) | ADORA2AADORA1ADORA2BADORA3TLR7 | |
| SCHEMBL20275365 | 0.69 | TLR7 (0.53) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575340-B2 | Purine derivatives and their pharmaceutical uses | GLAXOSMITHKLINE LLC (US) | 2013-11-05 | — | — | US | disclosed |
| US-20120315291-A1 | PURINE DERIVATIVES AND THEIR PHARMACEUTICAL USES | GLAXOSMITHKLINE LLC (US) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120315291-A1 | PURINE DERIVATIVES AND THEIR PHARMACEUTICAL USES | STING1, IFNG, IRF3 | ADORA2A 48/4885ADORA1 23/4885ADORA2B 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.